ObjectiveHealth | Arcare Center for Clinical Research

Research site

(Unclaimed)

Location

8924 Kanis Road, Little Rock, Alabama, United States of America

Site insights

Top conditions

Top treatments

Lanifibranor

Amine

K-877-ER

Firsocostat

Semaglutide

EmpaGliflozin

CSG452

Semicarbazide

Inclisiran

Cilofexor

Parent organization

This site is a part of ObjectiveHealth

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high d...

Enrolling

Metabolic Dysfunction-associated Steatohepatitis

Drug: Placebo

Drug: ECC4703

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatoh...

Active, not recruiting

NASH

Drug: K-877-ER

Drug: Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms